Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab
Zahra Castel-Ajgal, Claire Goulvestre, Sonia Zaibet, Jennifer Arrondeau, Marie Bretagne, Michaël Peyromaure, Frédéric Batteux, Jérôme Alexandre, François Goldwasser, Olivier Huillard
Topics & Concepts
MedicinePembrolizumabInternal medicineMetastatic Urothelial CarcinomaOncologyAutoantibodyUnivariate analysisAdverse effectGastroenterologyPopulationCarcinomaUrothelial carcinomaCancerImmunotherapyMultivariate analysisAntibodyImmunologyBladder cancerEnvironmental healthCancer Immunotherapy and BiomarkersBladder and Urothelial Cancer TreatmentsRenal cell carcinoma treatment